威廉亚洲官网
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
威廉亚洲博彩公司
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床威廉亚洲博彩公司
医学计算与公式
ICD-10/ICD-11疾病编码
医迅达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci williamhill asia 搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#优先审查#
60篇内容 | 1528人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=0b0e25e2913, topicName=优先审查, introduction=优先审查, content=null, image=null, comments=60, allHits=1528, url=https://h5.medsci.cn/topic?id=25729, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=5606, tagList=[TagDto(tagId=5606, tagName=优先审查)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1400127, encodeId=b139140012e8c, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=美国优先审查Keytruda/chemo联用作为鳞状非小细胞肺癌一线用药, objectType=article, longId=142416, objectId=31f514241615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31f514241615, replyNumber=0, likeNumber=63, createdTime=2018-07-05, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31f514241615, moduleTitle=美国优先审查Keytruda/chemo联用作为鳞状非小细胞肺癌一线用药, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=31f514241615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400126, encodeId=ec2514001269e, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=安斯泰来的AML药物获FDA优先审查, objectType=article, longId=139544, objectId=c604139544d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c604139544d4, replyNumber=0, likeNumber=43, createdTime=2018-06-01, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c604139544d4, moduleTitle=安斯泰来的AML药物获FDA优先审查, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c604139544d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400125, encodeId=08911400125f9, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA对罗氏Tecentriq的一线使用给予优先审查, objectType=article, longId=137599, objectId=747413e5997a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=747413e5997a, replyNumber=0, likeNumber=33, createdTime=2018-05-10, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=747413e5997a, moduleTitle=FDA对罗氏Tecentriq的一线使用给予优先审查, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=747413e5997a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400124, encodeId=975414001248d, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予Keytruda优先审查, objectType=article, longId=137090, objectId=1ced13e09014, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ced13e09014, replyNumber=0, likeNumber=59, createdTime=2018-05-04, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ced13e09014, moduleTitle=FDA授予Keytruda优先审查, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1ced13e09014)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400123, encodeId=a89b1400123bf, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=美国优先审查Sanofi,Regeneron的cemiplimab。, objectType=article, longId=136950, objectId=508213695093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508213695093, replyNumber=0, likeNumber=54, createdTime=2018-05-02, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508213695093, moduleTitle=美国优先审查Sanofi,Regeneron的cemiplimab。, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=508213695093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400122, encodeId=858a140012202, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=对Shire的HAE药物进行优先审查, objectType=article, longId=130444, objectId=065413044401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=065413044401, replyNumber=0, likeNumber=54, createdTime=2018-02-25, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=065413044401, moduleTitle=对Shire的HAE药物进行优先审查, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=065413044401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400121, encodeId=b83314001219e, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA对阿斯利康肿瘤治疗的Tagrisso进行优先审查, objectType=article, longId=124027, objectId=be6212402ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be6212402ecd, replyNumber=0, likeNumber=61, createdTime=2017-12-21, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be6212402ecd, moduleTitle=FDA对阿斯利康肿瘤治疗的Tagrisso进行优先审查, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=be6212402ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400120, encodeId=c2961400120c6, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, objectType=article, longId=94937, objectId=aed19493eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aed19493eed, replyNumber=0, likeNumber=63, createdTime=2017-04-08, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aed19493eed, moduleTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=aed19493eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400119, encodeId=52ad140011920, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=肝癌福音!美国FDA授予拜耳靶向抗癌药Stivarga优先审查资格,二线治疗晚期肝细胞癌, objectType=article, longId=86806, objectId=74ba86806dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ba86806dc, replyNumber=0, likeNumber=66, createdTime=2017-01-07, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ba86806dc, moduleTitle=肝癌福音!美国FDA授予拜耳靶向抗癌药Stivarga优先审查资格,二线治疗晚期肝细胞癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=74ba86806dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400118, encodeId=0b4b140011845, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=美国FDA授予辉瑞突破性乳腺癌新药Ibrance优先审查资格, objectType=article, longId=85251, objectId=9bd48525153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bd48525153, replyNumber=0, likeNumber=62, createdTime=2016-12-25, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bd48525153, moduleTitle=美国FDA授予辉瑞突破性乳腺癌新药Ibrance优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9bd48525153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400117, encodeId=5384140011e49, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=喜讯!FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌(NSCLC)优先审查资格和突破性药物资格, objectType=article, longId=77041, objectId=3754e70412b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3754e70412b, replyNumber=0, likeNumber=49, createdTime=2016-09-10, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3754e70412b, moduleTitle=喜讯!FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌(NSCLC)优先审查资格和突破性药物资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3754e70412b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400116, encodeId=339a14001167c, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予礼来单抗药物olaratumab治疗晚期软组织肉瘤的优先审查资格, objectType=article, longId=67744, objectId=aa4d6e74471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa4d6e74471, replyNumber=0, likeNumber=58, createdTime=2016-05-09, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa4d6e74471, moduleTitle=FDA授予礼来单抗药物olaratumab治疗晚期软组织肉瘤的优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=aa4d6e74471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400115, encodeId=f45a1400115b6, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病(ALL)的优先审查资格, objectType=article, longId=67544, objectId=c7dd6e544b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7dd6e544b6, replyNumber=0, likeNumber=47, createdTime=2016-05-06, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7dd6e544b6, moduleTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病(ALL)的优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c7dd6e544b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400114, encodeId=e352140011484, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格,将极大简化丙肝临床治疗, objectType=article, longId=61804, objectId=93ed618041a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ed618041a, replyNumber=0, likeNumber=61, createdTime=2016-01-09, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ed618041a, moduleTitle=吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格,将极大简化丙肝临床治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=93ed618041a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400113, encodeId=e19e140011376, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予多发性骨髓瘤新药daratumumab优先审查资格, objectType=article, longId=55963, objectId=8c7b559631b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7b559631b, replyNumber=0, likeNumber=58, createdTime=2015-09-11, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7b559631b, moduleTitle=FDA授予多发性骨髓瘤新药daratumumab优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8c7b559631b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400112, encodeId=53b614001121f, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予原发性胆汁性肝硬化治疗药物OCA优先审查资格, objectType=article, longId=55620, objectId=0b5e55620ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b5e55620ec, replyNumber=0, likeNumber=44, createdTime=2015-09-03, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b5e55620ec, moduleTitle=FDA授予原发性胆汁性肝硬化治疗药物OCA优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0b5e55620ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400111, encodeId=200014001115d, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, objectType=article, longId=24620, objectId=18ab2462050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ab2462050, replyNumber=0, likeNumber=56, createdTime=2013-09-20, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ab2462050, moduleTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=18ab2462050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400110, encodeId=f6771400110f4, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予拜耳多吉美(Nexavar)sNDA优先审查资格, objectType=article, longId=23456, objectId=461f234568d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461f234568d, replyNumber=0, likeNumber=55, createdTime=2013-08-30, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461f234568d, moduleTitle=FDA授予拜耳多吉美(Nexavar)sNDA优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=461f234568d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400109, encodeId=1b8214001097e, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA授予Exelixis公司抗癌药cabozantinib优先审查资格, objectType=article, longId=8446, objectId=1a8f844619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a8f844619, replyNumber=0, likeNumber=42, createdTime=2012-08-03, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a8f844619, moduleTitle=FDA授予Exelixis公司抗癌药cabozantinib优先审查资格, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1a8f844619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400108, encodeId=bab61400108e1, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, objectTitle=FDA优先审查利伐沙班和阿哌沙班新适应证, objectType=article, longId=4295, objectId=ced84295fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced84295fb, replyNumber=0, likeNumber=51, createdTime=2012-03-12, rootId=0, userName=yxch37, userId=80942248041, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced84295fb, moduleTitle=FDA优先审查利伐沙班和阿哌沙班新适应证, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ced84295fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
williamhill asia 话题小助手
关注
已关注
优先审查
2020-05-29
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
美国优先审查Keytruda/chemo联用作为鳞状非小细胞肺癌一线用药
63
0
2018-07-05
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
安斯泰来的AML药物获FDA优先审查
43
0
2018-06-01
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA对罗氏Tecentriq的一线使用给予优先审查
33
0
2018-05-10
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予Keytruda优先审查
59
0
2018-05-04
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
美国优先审查Sanofi,Regeneron的cemiplimab。
54
0
2018-05-02
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
对Shire的HAE药物进行优先审查
54
0
2018-02-25
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA对阿斯利康肿瘤治疗的Tagrisso进行优先审查
61
0
2017-12-21
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查
63
0
2017-04-08
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
肝癌福音!美国FDA授予拜耳靶向抗癌药Stivarga优先审查资格,二线治疗晚期肝细胞癌
66
0
2017-01-07
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
美国FDA授予辉瑞突破性乳腺癌新药Ibrance优先审查资格
62
0
2016-12-25
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
喜讯!FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌(NSCLC)优先审查资格和突破性药物资格
49
0
2016-09-10
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予礼来单抗药物olaratumab治疗晚期软组织肉瘤的优先审查资格
58
0
2016-05-09
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病(ALL)的优先审查资格
47
0
2016-05-06
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格,将极大简化丙肝临床治疗
61
0
2016-01-09
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予多发性骨髓瘤新药daratumumab优先审查资格
58
0
2015-09-11
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予原发性胆汁性肝硬化治疗药物OCA优先审查资格
44
0
2015-09-03
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格
56
0
2013-09-20
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予拜耳多吉美(Nexavar)sNDA优先审查资格
55
0
2013-08-30
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA授予Exelixis公司抗癌药cabozantinib优先审查资格
42
0
2012-08-03
回复
yxch37
(审核中...)
关注
已关注
前往app查看评论内容
#优先审查#
FDA优先审查利伐沙班和阿哌沙班新适应证
51
0
2012-03-12
回复
共60条
首页
上一页
下一页
尾页
页码:
3
/3页
20条/页
扫描二维码下载williamhill asia 医学APP
科室
订阅+
更多科室
工具
服务